Form 4: Cytek Biosciences Director Deborah Neff Granted Significant Equity Awards

Cytek Biosciences, Inc. Director Deborah J. Neff was granted 43,973 Restricted Stock Units and options to purchase 23,809 shares of common stock, with vesting scheduled for June 2026.

Summary

• Deborah J. Neff, a Director of Cytek Biosciences, Inc. (CTKB), acquired new equity awards on June 18, 2025.
• The awards consist of 43,973 Restricted Stock Units (RSUs) and options to purchase 23,809 shares of common stock.
• Both the RSU Award and the Director Stock Option are scheduled to vest 100% on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).
• The Director Stock Options have an exercise price of $3.07 per share and an expiration date of June 18, 2035.
• Following these transactions, Deborah J. Neff beneficially owns 43,973 Restricted Stock Units and 23,809 Director Stock Options directly.

Sentiment

Score: 6

Explanation: The document reports a routine grant of equity compensation to a director, which is a standard practice for aligning management and shareholder interests. It does not contain information that would significantly alter the company's financial outlook or operations, thus indicating a neutral to slightly positive sentiment.

Positives

• The grant of equity awards to Director Deborah J. Neff aligns her financial interests with those of the company's shareholders.
• These awards serve as an incentive for long-term commitment and performance from a key board member.

Future Outlook

The vesting of 43,973 Restricted Stock Units and 23,809 stock options is anticipated to occur on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, indicating future share issuance and potential minor dilution.

Industry Context

The granting of equity awards to directors is a common and standard practice across publicly traded companies, particularly within the biotechnology and life sciences sectors, serving to align the interests of board members with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The document, a Form 4, details a specific insider transaction and does not provide information on comparable companies, projects, or results within the industry.

Related Party Transactions

• Grant of 43,973 Restricted Stock Units and 23,809 Director Stock Options to Deborah J. Neff, a director of the company, as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon the vesting and exercise of these equity awards, balanced by improved alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Vesting of 43,973 Restricted Stock Units and 23,809 Director Stock Options on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Award, Director Compensation, Beneficial Ownership